Mathijssen RH - Search Results

1

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

2

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Sparreboom A, et al. Among authors: mathijssen rh. Clin Cancer Res. 1998 Nov;4(11):2747-54. Clin Cancer Res. 1998. PMID: 9829738 Clinical Trial.

3

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

Mathijssen RH, van Alphen RJ, de Jonge MJ, Verweij J, de Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G, Sparreboom A. Mathijssen RH, et al. Anticancer Drugs. 1999 Jan;10(1):9-16. doi: 10.1097/00001813-199901000-00002. Anticancer Drugs. 1999. PMID: 10194542 Clinical Trial.

4

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A. de Jonge MJ, et al. Among authors: mathijssen rh. J Clin Oncol. 2000 Jan;18(1):195-203. doi: 10.1200/JCO.2000.18.1.195. J Clin Oncol. 2000. PMID: 10623710

5

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Clin Cancer Res. 2001 Aug;7(8):2182-94. Clin Cancer Res. 2001. PMID: 11489791 Review.

6

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

7

Altered irinotecan metabolism in a patient receiving phenytoin.

Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Mathijssen RH, et al. Anticancer Drugs. 2002 Feb;13(2):139-40. doi: 10.1097/00001813-200202000-00004. Anticancer Drugs. 2002. PMID: 11901305

8

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A. Mathijssen RH, et al. Br J Cancer. 2002 Jul 15;87(2):144-50. doi: 10.1038/sj.bjc.6600447. Br J Cancer. 2002. PMID: 12107833 Free PMC article.

9

Modulation of irinotecan metabolism by ketoconazole.

Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Kehrer DF, et al. Among authors: mathijssen rh. J Clin Oncol. 2002 Jul 15;20(14):3122-9. doi: 10.1200/JCO.2002.08.177. J Clin Oncol. 2002. PMID: 12118026 Clinical Trial.

10

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Xie R, et al. Among authors: mathijssen rh. J Clin Oncol. 2002 Aug 1;20(15):3293-301. doi: 10.1200/JCO.2002.11.073. J Clin Oncol. 2002. PMID: 12149304

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters